Study of IBI-351 for KRAS G12C+ lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at people with advanced or spreading non-small cell lung cancer that has a KRAS G12C mutation, who have already taken the drug IBI-351. It aims to understand how well this drug works in everyday practice and why it might help you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body.
- Your cancer has a specific marker called KRAS G12C, found through a molecular test.
- You have already taken at least one dose of the drug IBI-351 between August 2024 and August 2025.
- You do not have a mix of lung cancer types, such as small cell or squamous cell, as the main part.
- You do not have other genetic changes (like EGFR, ALK, or ROS1) that have approved first-line treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs before surgery for people with a certain type of lung cancer (KRAS G12C). The goal is to see if these drugs can shrink the tumor and improve chances of successful surgery.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests a new drug called IBI3005, given with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It may help shrink tumors or slow their growth.
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.